Home > Insider Trading > Filing (0001077183-23-000140)

Filing Details

Accession Number:: 0001077183-23-000140
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-11-20 16:33:57
Reporting Period:: 2023-11-17

Accepted Time:: 2023-11-20 16:33:57
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1077183	Neogenomics Inc	NEO	Services-Testing Laboratories (8734)	742897368

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1951869	C Alicia Olivo	9490 Neogenomics Way Fort Myers FL 33912	General Counsel	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2023-11-17	2,669	$18.39	37,140	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Stock Option (Right to Buy)	$19.12		2026-09-30	1,046	1,046	Direct
Common Stock	Stock Option (Right to Buy)	$27.34		2027-05-01	1,024	1,024	Direct
Common Stock	Stock Option (Right to Buy)	$48.99		2028-05-01	516	516	Direct
Common Stock	Stock Option (Right to Buy)	$46.10		2028-08-01	1,117	1,117	Direct
Common Stock	Stock Option (Right to Buy)	$9.45		2029-05-01	22,222	22,222	Direct
Common Stock	Stock Option (Right to Buy)	$10.05		2029-09-01	55,332	55,332	Direct
Common Stock	Stock Option (Right to Buy)	$19.65		2030-05-11	36,508	36,508	Direct
Common Stock	Restricted Stock Unit	$0.00			19,508	19,508	Direct
Common Stock	Performance Stock Unit	$0.00	2026-05-11		19,508	19,508	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2026-09-30	1,046	1,046	Direct
2027-05-01	1,024	1,024	Direct
2028-05-01	516	516	Direct
2028-08-01	1,117	1,117	Direct
2029-05-01	22,222	22,222	Direct
2029-09-01	55,332	55,332	Direct
2030-05-11	36,508	36,508	Direct
	19,508	19,508	Direct
	19,508	19,508	Direct

Footnotes

This balance includes 311 shares that were acquired pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) since the date of the reporting person's last filing. The shares were acquired in transactions exempt from Section 16b-3.
On September 30, 2019, Ms. Olivo was granted 1,394 stock options. The options vested ratably over the first four anniversary dates of the grant date.
On May 1, 2020, Ms. Olivo was granted 1,024 stock options. The options vest ratably over the first four anniversary dates of the grant date.
On May 1, 2021, Ms. Olivo was granted 516 stock options. The options vest ratably over the first four anniversary dates of the grant date.
On August 1, 2021, Ms. Olivo was granted 1,117 stock options. The options vest ratably over the first four anniversary dates of the grant date.
On May 1, 2022, Ms. Olivo was granted 22,222 stock options. The options vest ratably over the first four anniversary dates of the grant date.
On September 1, 2022, Ms. Olivo was granted 55,332 stock options. The options vest ratably over the first four anniversary dates of the grant date.
On May 11, 2023, Ms. Olivo was granted 36,508 stock options. These options vest ratably over the first three anniversary dates of the grant date.
On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
Once vested, the shares of common stock are not subject to expiration.
On May 11, 2023, Ms. Olivo was granted 19,508 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 29,262. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company.